A Phase 1 Study Of Inotuzumab Ozogamicin (CMC-544) Administered In Combination With Rituximab In Subjects With B-Cell Non-Hodgkin's Lymphoma
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety: physical examinations (with vital signs) and laboratory test measurements.
A maximum of 16 months
Pfizer CT.gov Call Center
Japan: Pharmaceuticals and Medical Devices Agency